Norges Bank purchased a new stake in Pfenex Inc (NYSEAMERICAN:PFNX) during the fourth quarter, according to its most recent disclosure with the SEC. The firm purchased 305,910 shares of the biotechnology company’s stock, valued at approximately $976,000.
A number of other institutional investors also recently modified their holdings of PFNX. Renaissance Technologies LLC raised its holdings in Pfenex by 18.7% in the 3rd quarter. Renaissance Technologies LLC now owns 1,206,005 shares of the biotechnology company’s stock valued at $6,163,000 after acquiring an additional 189,705 shares during the last quarter. Vanguard Group Inc raised its holdings in Pfenex by 2.9% in the 3rd quarter. Vanguard Group Inc now owns 1,219,880 shares of the biotechnology company’s stock valued at $6,233,000 after acquiring an additional 34,844 shares during the last quarter. BlackRock Inc. raised its holdings in Pfenex by 17.7% in the 3rd quarter. BlackRock Inc. now owns 1,550,390 shares of the biotechnology company’s stock valued at $7,923,000 after acquiring an additional 233,517 shares during the last quarter. Falcon Point Capital LLC raised its holdings in Pfenex by 3.3% in the 4th quarter. Falcon Point Capital LLC now owns 80,205 shares of the biotechnology company’s stock valued at $256,000 after acquiring an additional 2,590 shares during the last quarter. Finally, JPMorgan Chase & Co. raised its holdings in Pfenex by 678.0% in the 3rd quarter. JPMorgan Chase & Co. now owns 90,151 shares of the biotechnology company’s stock valued at $461,000 after acquiring an additional 78,563 shares during the last quarter.
A number of analysts have commented on the stock. William Blair reiterated a “buy” rating on shares of Pfenex in a report on Tuesday, April 2nd. Zacks Investment Research upgraded shares of Pfenex from a “hold” rating to a “buy” rating and set a $5.50 price target for the company in a report on Friday, March 15th. Finally, Wedbush restated an “outperform” rating on shares of Pfenex in a report on Thursday, March 7th.
Shares of NYSEAMERICAN PFNX opened at $5.61 on Tuesday. Pfenex Inc has a 1 year low of $3.13 and a 1 year high of $8.42.
Pfenex (NYSEAMERICAN:PFNX) last announced its quarterly earnings results on Monday, March 11th. The biotechnology company reported ($0.22) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.31) by $0.09. The firm had revenue of $3.35 million for the quarter, compared to analyst estimates of $6.28 million.
ILLEGAL ACTIVITY WARNING: This piece of content was originally posted by The Lincolnian Online and is owned by of The Lincolnian Online. If you are accessing this piece of content on another domain, it was illegally copied and republished in violation of U.S. and international trademark & copyright law. The legal version of this piece of content can be viewed at https://www.thelincolnianonline.com/2019/05/07/norges-bank-purchases-new-position-in-pfenex-inc-pfnx.html.
Pfenex Company Profile
Pfenex Inc, a clinical-stage development and licensing biotechnology company, focuses on developing protein therapies for unmet patient needs. Its lead product candidates include PF708, a therapeutic equivalent drug candidate to Forteo (teriparatide) for the treatment of osteoporosis; and novel anthrax vaccine candidates, such as Px563L and RPA563 that have completed Phase Ia clinical study.
Further Reading: Bear Market – How and Why They Occur
Want to see what other hedge funds are holding PFNX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfenex Inc (NYSEAMERICAN:PFNX).
Receive News & Ratings for Pfenex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfenex and related companies with MarketBeat.com's FREE daily email newsletter.